Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432049 | 0.91 | TSHR (0.42) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL7709947 | 0.91 | TSHR (0.42) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL4307337 | 0.88 | TSHR (0.46) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL29134968 | 0.87 | TSHR (0.39) | TSHRHPGD | |
| SCHEMBL21624969 | 0.84 | TSHR (0.41) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL2435317 | 0.84 | — | — | |
| SCHEMBL673221 | 0.82 | TSHR (0.40) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL28029833 | 0.82 | TSHR (0.42) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL21385196 | 0.81 | TSHR (0.39) | TSHRHPGD | |
| SCHEMBL7563890 | 0.80 | TSHR (0.45) | TSHRHPGDALDH1A1TP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194511-B1 | COMPRISING POLYMERIZABLE MONOMER CONTAINING SULFUR-CONTAINING (METH)ACRYLATE POLYMERIZABLE MONOMER AND PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2001-02-27 | — | — | US | claimed |
| US-20260140398-A1 | OPTICAL MATERIAL COMPOSITION, CURED BODY, OPTICAL ARTICLE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-3901185-B1 | CURABLE COMPOSITION FOR OPTICAL MATERIALS, AND OPTICAL MATERIAL | TOKUYAMA CORP (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4696722-A1 | (METH)ACRYLATE, CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12552745-B2 | Compound for optical materials, curable composition, cured body, and optical article | TOKUYAMA CORPORATION (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-4644435-A1 | URETHANE (METH)ACRYLATE, CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENSES, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2025-11-05 | — | — | EP | disclosed |
| EP-4636464-A1 | CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-4636466-A1 | CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-4636465-A1 | CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12428390-B2 | Chromene compound and photochromic optical article | TOKUYAMA CORPORATION (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-1130038-B1 | PHOTOCHROMIC CURABLE COMPOSITION | TOKUYAMA CORP (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20050263745-A1 | Method of preparing a ceramic artificial crown and a preparation kit used therefor | TOKUYAMA CORPORATION (JP) | 2005-12-01 | — | — | US | disclosed |
| EP-1427763-A1 | METHOD FOR THE PRODUCTION OF POLYMERS AND COPOLYMERS FROM ACRYLIC COMPOUNDS | Röhm GmbH & Co. KG (DE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003048176-A1 | CATALYST FOR PRODUCING (CO)POLYMERS OF (METH)ACRYLIC COMPOUNDS | Röhm GmbH & Co. KG (DE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003029310-A1 | METHOD AND DEVICE FOR PRODUCING A HIGHLY MOLECULAR POLY(METH)ACRYLATE | RÖHM GBMH & CO.KG (DE) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003022897-A1 | METHOD FOR THE PRODUCTION OF POLYMERS AND COPOLYMERS FROM ACRYLIC COMPOUNDS | Röhm GmbH & Co. KG (DE) | 2003-03-20 | — | — | WO | disclosed |
| EP-0940694-B1 | Photochromic curable composition | TOKUYAMA CORP (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1130038-A1 | CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6194511-B1 | COMPRISING POLYMERIZABLE MONOMER CONTAINING SULFUR-CONTAINING (METH)ACRYLATE POLYMERIZABLE MONOMER AND PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0940694-A1 | Photochromic curable composition | TOKUYAMA CORPORATION (JP) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552745-B2 | Compound for optical materials, curable composition, cured body, and optical article | C5, SCO2, ZYX | TSHR 3533/4885HPGD 4118/4885ALDH1A1 1308/4885 |
| US-20260140398-A1 | OPTICAL MATERIAL COMPOSITION, CURED BODY, OPTICAL ARTICLE, LENS, AND SPECTACLES | CRYAA, FEM1B, MAPRE1 | TSHR 4218/4885HPGD 2691/4885ALDH1A1 588/4885 |
| US-12428390-B2 | Chromene compound and photochromic optical article | CRY1, CRY2, RAD51 | TSHR 2223/4885HPGD 2457/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.